After the first 3 assessment cycles, the trial was explained to participants. They were assured of confidentiality and that their participation was entirely voluntary. Those who agreed to participate signed the informed consent form. All of them agreed to take tablets from days 1 to 5 of their menstrual period for the 3 consecutive intervention cycles.